TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

IMCIVREE

SETMELANOTIDE ACETATE Melanocortin 4 Receptor Agonists
Metabolic Approved 2020-11-25
3
Indications
--
Phase 3 Trials
3
Priority Reviews
5
Years on Market

Details

Status
Prescription
First Approved
2020-11-25
Routes
SUBCUTANEOUS
Dosage Forms
SOLUTION

Companies

Active Ingredient: SETMELANOTIDE ACETATE

IMCIVREE Approval History

Loading approval history...

What IMCIVREE Treats

5 indications

IMCIVREE is approved for 5 conditions since its original approval in 2020. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Obesity
  • Bardet-Biedl Syndrome
  • Pro-opiomelanocortin Deficiency
  • Proprotein Convertase Subtilisin/Kexin Type 1 Deficiency
  • Leptin Receptor Deficiency
Source: FDA Label
πŸ”¬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
⭐

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
πŸ“Š

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

IMCIVREE FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

IMCIVREE is indicated to reduce excess body weight and maintain weight reduction long term in adults and pediatric patients aged 2 years and older with syndromic or monogenic obesity due to: Bardet-Biedl syndrome (BBS) [see Dosage and Administration ] Pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency as determined by an FDA-approved test demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS) [see Dosage and Administration ]. Limitations ...

IMCIVREE Patents & Exclusivity

Latest Patent: Jul 2034
Exclusivity: Dec 2031

Patents (3 active)

US11129869 Expires Jul 4, 2034
US8039435 Expires Aug 21, 2032
US9458195 Expires Oct 13, 2027

Exclusivity

NPP Until Dec 2027
ODE-336 Until Nov 2027
ODE-402 Until Jun 2029
ODE-508 Until Dec 2031
ODE-509 Until Dec 2031
Source: FDA Orange Book

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.